Our results similarly showed no association between DAPK methylation and clinicopathological features of DLBCL, in relation to gender (OR = 0.88, 95% CI (0.48 1.60), P = 0.675) (Fig 5A), age (OR = 1.09, 95% CI (0.60, 1.99), P = 0.775) (Fig 5B), IPI (OR = 1.20, 95% CI (0.63, 2.27), P = 0.575) (Fig 5C), B symptoms (OR = 0.76, 95% CI (0.38, 1.51), P = 0.425) (Fig 5D), LDH (OR = 0.95, 95% CI (0.48, 1.89), P = 0.878) (Fig 5E), and BCL-2 expression (OR = 3.49, 95% CI (0.16, 74.37), P = 0.423) (Fig 5F). Here, DAPK1 is linked to diffuse large B-cell lymphoma.